Pharmacyclics — Technical Presentation (June 2012)
24 slides from Pharmacyclics's technical presentation, Jun 19, 2012
Slide 1: Highly Active and Tolerable Treatment: Interim Results of Phase Ib/II Study
(13276 8 Highly Pcuve and Tolerable i Ue Treatment LL) Patients: Interim R eE-otac PR Ib/Il Stud y SUSAN O'BRIEN, MD', RICHARD R. FURMAN, MD?, STEVEN E. COUTRE, MD?, JANA. aps a PHD rete BLUM, MD‘, JEFF SHARMAN, MD°, JAN W. FLINN, GRANT, MD’, NYLA A. HEEREMA, PHD‘, AMY J. SOUREON, Buc TASHICEA NAVAR
Slide 2: Bruton's Tyrosine Kinase (BTK)
Bruton’s Tyrosine Kinase (BTK) A critical kinase for lymphoma cell survival and proliferation + BTK is expressed and functional across non-T-cell hematopoietic lineages + BTK functions downstream in a variety of receptors. + Essential element of B-cell receptor signaling + Chemokine mediated migrati
Slide 3: Ibrutinib (PCI-32765), a selective inhibitor of BTK
Ibrutinib (PCI-32765), a selective inhibitor of BTK - Forms a specific bond with cysteine-481 in BTK > Highly potent BTK inhibition at IC50 =0.5 nM > Orally administered with once daily dosing resulting in 24-hr target inhibition > No cytotoxic effect on T-cells or NK-cells + In CLL cells promotes a
Slide 4: PCYC-1102-CA: Phase IB/II in CLL/SLL
PCYC-1102-CA: Phase IB/II in CLL/SLL PCYC-1102-CA Total enrollment 117 patients Dates enrolled 20th May 10 — 27% Jul 14 Relapsed/Refractory 420 mg/d (n=27) Median follow-up 17.5 months Treatment Naive = 65 yrs 840 mg/d (1 Median follow-up h-risk Relapsed/Refractory 420 mg/d (n=25) Median follow-up 7
Slide 5: PCYC-1102-CA: Phase IB/II in CLL/SLL
PCYC-1102-CA: Phase IB/I n CLL/SLL Relapsed/Refractory 420 mg/d (n Median follow. 17.5 months PCYC-1102-CA PFS Total enrollment dbsatwot 417 patients ‘ion Dates enrolled O'Brien 20% May 10 — ASH 2011 27" Jul 14 presentation Relapsed/Refractory 840 mg/d (n=34) Median follow-up 13.8 months
Slide 6: PCYC-1102-CA: Phase IB/II in CLL/SLL (Treatment Naive)
PCYC-1102-CA: Phase IB/II in CLL/SLL (Treatment Naive 2 65 yrs population) Treatment Naive = 65 yrs 420 mg/d (n=26) PCYC-1102-CA Median follow-up 14.4 months 117 patients Full safety Dates enrolled and 20% May 10 efficacy — 27% Jul 11 data NY Treatment Naive = 65 yrs 840 mg/d (n=5)* Median follow-up
Slide 7: Study Design
Study Design: Ibrutinib as a single agent for treatment naive CLL/SLL patients aged 65 and older Two fixed continuous doses 420 mg/day or 840 mg/day until disease progression Objectives to evaluate: — Safety — Response rate — PFS
Slide 8: Patient Characteristics
Patient Characteristics (Treatment-Naive 2 65 yrs) Age, years Median (Range): 270 years, tf (%) ECOG Performance Status, # (2%) ° 1 2 Microgiobulin > 3mg/L Cytopenia at baseline, # (%) HGB < 11g/dL Platelets < 100,000/pL HGB < 11¢/dL or PLT < 100,000 wt Prognostic Markers, # (%) IgVH unmutated: Del(
Slide 9: PCYC-1102-CA: Patient Disposition
PCYC-1102-CA: Patient Disposition (Treatment Naive 2 665 yrs) 420 mg/d 840 me/d ‘Subjects Discontinued, #f (2%) 4 (15) Primary Reasons for Discontinuation, # (%) Disease Progression a(ay 0(0) Adverse event 2 (8) 1.(20)* Unrelated: viral syndrome Unrelated: Worsening GI hemorrhage Possibly related: f
Slide 10: Common AEs regardless of relationship
Common AEs (> 20 a regardless of relationship (Treatment Naive 2 65 yi Diarrhea Nausea Fatigue Dyspepsia Rash Contusion/Ecchymosis Dizziness Hypertension Vomiting % 10% 20% 30% 40% 50% 60% 70% Mm Grade1 MM Grade2 Mmm Grade3 = MI Grade 4
Slide 11: Safety
Safety (Treatment Naive 2 65 yrs) Grade 3 Grade 4 Grade 3/4 hematology toxicity, # (%) 2) 26) Neutropenia ° ° Anemia 13) 103) Thrombocytopenia 23) 103) Grade 3/4 non-hematology toxicity regardless of relatedness 6 (19) ° Diarrhea 4(a3) ° Hyponatremia 2() ° Enterocolitis hemorrhagic 213) ° Grade 3/4
Slide 12: Median Percent Change From Baseline
Median Percent Change From Baseline ent surge in lymphocytes, resolution of lymph nodes ALC AU single ent Neri sine oem PREELEL ER ESS Cycles
Slide 13: Response Criteria
Response Criteria - NHL IWG criteria’ were applied to SLL cases + The 2008 IWCLL criteria? were applied to CLL cases with the following modifications: — Treatment-related lymphocytosis, in the absence of other parameters meeting the criteria for PD, was not considered PD in line with modified IWCLL
Slide 14: Best Response
Best Response cR PR Nodal sD PD NE Medi ‘420 mg/d 840 mg/d (N=26) (N=5) n fia Median f/u = mos mos #(%) # (%) 3 12) ° 18 (69) 2 (40) 3 (12) 4 (20) 1(4) 1 (20) ° ° 1 (4) 1 (20) *Per IWCLL 2008 criteria 3 (10) 20 (65) 4 (13) 26) ° 26)
Slide 15: PCYC-1102-CA: Best Response by Risk Features
PCYC-1102-CA: Best Response by Risk Features (Treatment Naive 2 65 yrs) ORR %(n) | CR %(n) All Patients 31 74 (23) 10 (3) = 70 years age oe) 70 (16) 13 (3) Hgb < 11 g/dl or PLT < 100K/yL at 19 79 (15) 41 (2) screening IgVH unmutated 13 92 (12) 15 (2) Del17p present 2 100 (2) 0 (0) B2 Microglobulin >
Slide 16: Response Rate by Cycle (Treatment Naive)
(Treatment Naive 2 65 yrs) )—Median f/u 14.4 months Response Rate % a oe $6 Ss N 3 s 10% 77% 73% 69% 69% 1% 46% 30% 27% il| i la Cycle 2 Cycle 5 Cycle 8 Cycle 11 CR mi PR mg Nodal Response Best Response
Slide 17: Platelet Counts in Patients with Cytopenias
Platelet Counts in Patients with Pi Cytopenias Platelets 50% Hgb 50% 0% 10% 20% 30% 40% 50% 60% “Sustained improvement is defined as improvement in pretreatment cytopenia by >50%, or achieving a Hgb >11 g/dL OR pits >100,000 sustained for = 60 days without blood transfusion
Slide 18: Median Serum Ig Levels, Treatment Naive
Median Serum Ig Levels, 2 65 yrs Treatment Naive Patients* during Treatment with Ibrutinib Monotherapy s 1gA serum TgWt rerum 140 Serum 20 Se gS 120 106; 50 100 93 “Bg [ oe. 30 27.4 60 22 46 2u 40 = 10 ° ° md 2 2 € Sm 2 2S EF 2 5 & € 2565 2 Bs 8 2285 228 n=24 n=2t na1S 25 ns20 ne18 nat “Patients on
Slide 19: PFS Probability
PFS Probability rs) Estimated 15 mo PFS at 420mg/d = 96% 104 oo os 74 os os oa os 024 o4a4 oo a ee ee ee ee 420 mg/day — Naive (N=26) 840 mg/day — Naive (N=5) Data cut-off of 13MAR2012 2004 #6 8 10 12 Months on Study 14°16 «18 20
Slide 20: Cumulative Best Response: Relapsed/Refractory vs Treatment Naive
Cumulative Best Response (IWCLL*): Comparison of Relapsed/Refractory (n=27) and Treatment Naive = 65 yrs (n=26) populations at 4220 mg Faster Time Higher ORR Ex to Response 80% sz 70% @ 90% = 5 40% 34% ° Z 30% 27% th se = F pe 19% 46% 20% es | 0% ™N RR ™N RR TN RR Cycle 2 Cycle 5 ‘Cycle 11 “nodal re
Slide 21: Relapsed/Refractory PFS by Dose
(Relanesdleracionyy By dose lity PFS Probal Estimated 18 mo PFS at 420mg/d = 87.7% a rl 420 mg/day (N=27) 840 mg/day (N=34) o 2 4 6 8 10 12 14 16 18 20 Months on Study Data cut-off of 13MAR2012 2,
Slide 22: PFS Probability (Relapsed/Refractory)
PFS Probability (Relapsed/Refractory) Del 17p Status IgVH Status Del 17p-No (N=36) Del 17p-Yes (N=20) oe 07 06 03 o1 z _ IgVH unmutated-No (N=19) —— IgVH unmutated—Yes (N=42) o 2 4 6 6 10 12 4 16 18 20 0 2 4 6 & 10 12 4 16 18 20 Months on Study Data cut-off of 13MAR2012 2
Slide 23: Summary
Summary Ibrutinib administered as a single-agent to patients = 65 years with treatment naive CLL: + Resulted in 81% of patients achieving an IWCLL response with estimated 15-month PFS of 96% with 420mg/d suggesting early durability of treatment benefit = Responses to the single agent include complet
Slide 24: Acknowledgement
Acknowledgement All the patients and their families who participated in the study Investigators and clinical research staff from all the clinical centers Pharmacyclics, Inc.